Filtered By:
Condition: Heart Attack
Management: Insurance
This page shows you your search results in order of date. This is page number 18.
Order by Relevance | Date
Total 515 results found since Jan 2013.
The Impact of Abdominal Aortic Aneurysm on Cardiovascular Diseases
Int Heart J. 2021;62(6):1235-1240. doi: 10.1536/ihj.21-328.ABSTRACTCardiovascular diseases (CVDs) including myocardial infarction (MI) and stroke are often diagnosed in patients with abdominal aortic aneurysm (AAA). However, little has been reported regarding the incidence.Patients with AAA were selected from the National Health Insurance system in South Korea between 2009 and 2015. A total of 10,822 participants with a new diagnosis of AAA were included. Propensity score matching by age and sex with patients in whom AAA was not diagnosed was used to select the control group of 32,466 participants. Primary endpoints includ...
Source: International Heart Journal - December 2, 2021 Category: Cardiology Authors: Kyung Jai Ko Ju Hwan Yoo Hyung Jin Cho Mi Hyeong Kim Kang Woong Jun Kyung Do Han Jeong Kye Hwang Source Type: research
The Impact of Urate-Lowering Therapy in Post-Myocardial Infarction Patients: Insights from a Population-Based, Propensity Score-Matched Analysis
Clin Pharmacol Ther. 2021 Oct 31. doi: 10.1002/cpt.2473. Online ahead of print.ABSTRACTThe role of urate-lowering therapy (ULT) for the primary prevention of cardiovascular events has been widely discussed, but its evidence for the secondary prevention of myocardial infarction (MI) is limited. Therefore, we conduct a population-based, propensity score-matched cohort study to investigate the cardiovascular outcomes among post-MI patients with and without ULT. A total of 19,042 newly diagnosed in-hospital MI patients were selected using the Taiwan National Health Insurance Database between 1 January 2005 and 31 December 2016...
Source: Clinical Pharmacology and Therapeutics - October 31, 2021 Category: Drugs & Pharmacology Authors: Chi-Jung Tai Chin-Chung Wu Kun-Tai Lee Tzyy-Guey Tseng Hui-Chun Wang Fang-Rong Chang Yi-Hsin Yang Source Type: research
New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Risk for ischemic stroke and coronary heart disease associated with migraine and migraine medication among older adults
ConclusionsOlder adults with migraine are at increased risk for ischemic stroke. The risk for ischemic stroke among older adults with migraine may differ by migraine medication classes.
Source: The Journal of Headache and Pain - October 13, 2021 Category: Neurology Source Type: research
Risk of Cardiovascular Events and Medical Cost of Dapagliflozin and Dipeptidyl Peptidase-4 Inhibitors
This study compared dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, and dipeptidyl peptidase-4 inhibitors (DPP-4i) with regard to cardiovascular (CV) event incidence and direct medical costs during type 2 diabetes treatment. A retrospective cohort study was conducted using national health insurance claims data from September 1, 2014, to June 30, 2018, of patients in Korea. Patients who were prescribed dapagliflozin and DPP-4i for the first time were included. The primary outcome was the incidence of a composite of major adverse CV events (MACEs)—nonfatal myocardial infarction, nonfatal stroke, or in-hospital ...
Source: Frontiers in Pharmacology - September 28, 2021 Category: Drugs & Pharmacology Source Type: research
Moderate-Intensity Statins Plus Ezetimibe vs. High-Intensity Statins After Coronary Revascularization: A Cohort Study
ConclusionsPatients undergoing a coronary revascularization procedure who received moderate-intensity statins plus ezetimibe showed similar rates of major adverse cardiovascular events as patients who received high-intensity statins.
Source: Cardiovascular Drugs and Therapy - September 17, 2021 Category: Cardiology Source Type: research
